Protagenic Historical Income Statement
| PTIX Stock | USD 0.65 0.04 6.56% |
Historical analysis of Protagenic Therapeutics income statement accounts such as Other Operating Expenses of 4.3 M, Cost Of Revenue of 26.8 K, Total Operating Expenses of 5.7 M or Income Tax Expense of 1.9 can show how well Protagenic Therapeutics performed in making a profits. Evaluating Protagenic Therapeutics income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Protagenic Therapeutics's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining Protagenic Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Protagenic Therapeutics is a good buy for the upcoming year.
Protagenic |
About Protagenic Income Statement Analysis
Protagenic Therapeutics Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Protagenic Therapeutics shareholders. The income statement also shows Protagenic investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
Protagenic Therapeutics Income Statement Chart
Add Fundamental
Total Revenue
Total revenue comprises all receipts Protagenic Therapeutics generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Protagenic Therapeutics. It is also known as Protagenic Therapeutics overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Operating Income
Operating Income is the amount of profit realized from Protagenic Therapeutics operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Protagenic Therapeutics is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.Most accounts from Protagenic Therapeutics' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Protagenic Therapeutics current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Protagenic Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. For more information on how to buy Protagenic Stock please use our How to Invest in Protagenic Therapeutics guide.At this time, Protagenic Therapeutics' Total Operating Expenses is fairly stable compared to the past year. Research Development is likely to rise to about 3.5 M in 2024, whereas Depreciation And Amortization is likely to drop slightly above 26.8 K in 2024.
| 2021 | 2022 | 2023 | 2024 (projected) | Reconciled Depreciation | 37.0 | 30.0 | 1.6K | 1.7K | Interest Income | 33.2K | 185.8K | 303.2K | 318.4K |
Protagenic Therapeutics income statement Correlations
Click cells to compare fundamentals
Protagenic Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Protagenic Therapeutics income statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Depreciation And Amortization | 347.0 | 3.2K | 286.0 | 30.0 | 28.2K | 26.8K | |
| Interest Expense | 15.9K | 246.2K | 496.9K | 137.5K | 107.7K | 87.3K | |
| Selling General Administrative | 1.3M | 1.9M | 3.0M | 2.0M | 1.2M | 1.1M | |
| Gross Profit | (347.0) | (339.0) | (286.0) | (30.0) | (28.2K) | (26.8K) | |
| Other Operating Expenses | 2.1M | 2.6M | 4.1M | 3.6M | 4.5M | 4.3M | |
| Operating Income | (2.1M) | (2.6M) | (4.1M) | (3.6M) | (4.5M) | (4.8M) | |
| Ebit | (2.1M) | (2.6M) | (4.1M) | (3.4M) | (4.5M) | (4.3M) | |
| Ebitda | (2.1M) | (2.6M) | (4.1M) | (3.4M) | (4.5M) | (4.3M) | |
| Cost Of Revenue | 347.0 | 339.0 | 286.0 | 30.0 | 28.2K | 26.8K | |
| Total Operating Expenses | 2.1M | 2.6M | 4.1M | 3.6M | 4.5M | 5.7M | |
| Income Before Tax | (1.8M) | (2.5M) | (4.5M) | (3.6M) | (5.0M) | (5.3M) | |
| Total Other Income Expense Net | 335.2K | 2.9K | (382.5K) | 2.3K | (473.5K) | (497.2K) | |
| Net Income | (1.8M) | (2.8M) | (5.0M) | (3.6M) | (5.0M) | (5.3M) | |
| Income Tax Expense | 15.9K | 246.2K | 463.7K | 46.1K | 2.0 | 1.9 | |
| Research Development | 807.9K | 699.8K | 1.1M | 1.6M | 3.3M | 3.5M | |
| Net Income From Continuing Ops | (1.8M) | (2.5M) | (4.5M) | (3.6M) | (3.9M) | (3.7M) | |
| Net Income Applicable To Common Shares | (2.6M) | (1.8M) | (2.5M) | (4.5M) | (4.1M) | (3.9M) | |
| Net Interest Income | (13.1K) | (245.7K) | (463.7K) | 48.3K | 176.5K | 185.3K | |
| Interest Income | 2.8K | 502.0 | 33.2K | 185.8K | 303.2K | 318.4K | |
| Reconciled Depreciation | 339.0 | 286.0 | 37.0 | 30.0 | 1.6K | 1.7K |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Protagenic Stock Analysis
When running Protagenic Therapeutics' price analysis, check to measure Protagenic Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Protagenic Therapeutics is operating at the current time. Most of Protagenic Therapeutics' value examination focuses on studying past and present price action to predict the probability of Protagenic Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Protagenic Therapeutics' price. Additionally, you may evaluate how the addition of Protagenic Therapeutics to your portfolios can decrease your overall portfolio volatility.